Hepatitis A Live Attenuated Vaccine and Planned Forward Stock Split 2-1

SHENZHEN, China, Oct. 7 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce that its Hepatitis A Live Attenuated Vaccine (Brand name: Mevac-A) associate operation plant has obtained the GMP Certificate (Good Manufacturing Practice See Description http://en.wikipedia.org/wiki/Good_manufacturing_practice) from the Russian FDA. http://www.who.int/hiv/HIVCP_RUS.pdf

Since on or about September 24, 2009 when Mellow Hope announced through its exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd http://www.ty-pharm.com/en/index.asp that it has been granted H1N1 license by SFDA (China Authority) http://eng.sfda.gov.cn/eng interests in H1N1 began to grow Internationally with the company. Mellow Hope is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd for International marketing and sales.

New contracts and sales progress on H1N1 will be disclosed as they occur in subsequent HTDS press releases.

In other company news and events the company with this release brings attention to its Pink Sheets filing dated October 6, 2009 Supplemental Information- Forward Stock Split 2-1 HTDS Naked Short Positions and Remedies.

In summary, HTDS is considering having its shareholders approve a resolution on to make a two for one stock forward split. After due consideration, HTDS directors are recommending that the shareholders approve amending and restating our Articles of Incorporation in order to consolidate numerous amendments in the Articles that have occurred over the years, to create a two-for-one forward split, to prepare the Company to move up to the OTC Bulletin Board, and to add certain anti-takeover and other provisions. HTDS sees this forward split as one way to force short sellers to cover their current positions. Other remedies are also under consideration to thwart the short sellers or "oversold" positions of HTDS.

To receive regular updates on HTDS please sign up or opt in with your email address at this link http://www.minamargroup.com/updates/

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk; Investor Relations Department, (302) 357-9915 (IR); 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A); Corporate Matters, www.minamargroup.com (M&A), www.minamargroup.net (IR)

SOURCE Hard to Treat Diseases